150 related articles for article (PubMed ID: 20712081)
1. Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
Kahl BS; Cheson BD; Friedberg JW
Clin Adv Hematol Oncol; 2010 May; 8(5):1-16. PubMed ID: 20712081
[TBL] [Abstract][Full Text] [Related]
2. Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana.
Czuczman MS; Rummel MJ
Clin Adv Hematol Oncol; 2010 Feb; 8(2):A1-11. PubMed ID: 20391648
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
4. Hematologic malignancies: new developments and future treatments.
Cheson BD
Semin Oncol; 2002 Aug; 29(4 Suppl 13):33-45. PubMed ID: 12170431
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.
Plosker GL; Carter NJ
Drugs; 2008; 68(18):2645-60. PubMed ID: 19093705
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
Rummel MJ; Mitrou PS; Hoelzer D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
[TBL] [Abstract][Full Text] [Related]
8. In vitro studies with bendamustine: enhanced activity in combination with rituximab.
Rummel MJ; Chow KU; Hoelzer D; Mitrou PS; Weidmann E
Semin Oncol; 2002 Aug; 29(4 Suppl 13):12-4. PubMed ID: 12170426
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
Rummel MJ
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S7-10. PubMed ID: 18760709
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
Cheson BD; Crawford J
Br J Haematol; 2015 May; 169(4):528-33. PubMed ID: 25752751
[TBL] [Abstract][Full Text] [Related]
12. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
Hoy SM
Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
[TBL] [Abstract][Full Text] [Related]
13. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Ujjani C; Cheson B
Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
Brugger W; Ghielmini M
Oncologist; 2013; 18(8):954-64. PubMed ID: 23900001
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Cvetković RS; Perry CM
BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Elefante A; Czuczman MS
Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
[TBL] [Abstract][Full Text] [Related]
19. Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
Rummel M
J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 6():S1-14; quiz S15. PubMed ID: 20876549
[TBL] [Abstract][Full Text] [Related]
20. Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
Burke JM; van der Jagt RH; Flinn IW; Craig MD; Chen L; Morganroth J; Munteanu MC; MacDonald DA
Cancer Chemother Pharmacol; 2015 Jul; 76(1):211-6. PubMed ID: 26006703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]